title: [Blocking enhancive effect of vascular endothelial growth factor on proliferation of rhabdomyosarcoma cell line RH4 by avastin].
abstract: OBJECTIVE
  Vascular endothelial growth factor (VEGF) signal pathway is a hot spot in recent tumor research, but its role in rhabdomyosarcoma (RMS) has rarely been reported, and its mechanism is unclear. This study was to investigate the expression of VEGF and its receptors (VEGFR) in RMS cell line RH4 to reveal the mechanism of VEGF signal pathway, and explore the therapeutic value of Avastin in RMS in vitro.
  
  
  METHODS
  Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expression of VEGF, VEGFR1, VEGFR2, and VEGFR3 mRNA in RH4 cells. ELISA was used to detect the concentration of VEGF in supernatant. Western blot was used to detect the expression of VEGFR1 protein. The effects of VEGF and Avastin on RH4 cell growth were evaluated by direct cell counting.
  
  
  RESULTS
  RH4 cells expressed VEGF at a high level and secreted VEGF to culture media. RH4 cells only expressed VEGFR1, did not express VEGFR2 and VEGFR3. VEGF promoted the growth of RH4 cells in a dose-dependent manner within a concentration range of 0-100 ng/ml, this effect could be blocked by 10-40 microg/ml Avastin.
  
  
  CONCLUSIONS
  VEGF can promote the growth of RMS cell through VEGFR1, and this effect can be blocked by Avastin.
authors.affiliation: School of Basic Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, P. R. China.
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Li
authors.forename: Yan-Xia
authors.initials: YX
authors.lastname: Shi
authors.forename: Rou-Jun
authors.initials: RJ
authors.lastname: Peng
authors.forename: Mei-Qin
authors.initials: MQ
authors.lastname: Zhu
authors.forename: Yi-Yuan
authors.initials: YY
authors.lastname: Wan
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015153:Blotting, Western; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012208:Rhabdomyosarcoma / Q000378:metabolism / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D040281:Vascular Endothelial Growth Factor Receptor-1